Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals

Rhizen Pharmaceuticals

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Asthma; Healthy Volunteers

Treatments: Drug: Placebo; Drug: RP3128

Study type: Interventional

Funder types: Industry

Identifiers

NCT02958982

RP3128-1601

Details and patient eligibility

About

RP3128 is a calcium release activated calcium (CRAC) channel modulator. The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending dose(s) of RP3128 in healthy volunteers and to evaluate the effect on late phase asthmatic response to allergen challenge in patients with mild asthma.

Full description

The study consists of three parts; Part 1: single ascending dose (SAD), Part 2: multiple ascending dose (MAD) in healthy volunteers and Part 3: proof of concept (POC) study in mild asthmatics. There will be 5 cohorts in SAD and 3 cohorts in MAD, the doses used in the MAD will be based on emerging safety, tolerability and pharmacokinetics (PK) from Part 1 (SAD). POC is a randomized, placebo- controlled, double blind, two period cross-over, proof of concept study in male and female of non child bearing potential with history of mild asthma. the highest identified dose of RP3128 in Part 2 (MAD) will be considered for POC

Enrollment: 57 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male and non-childbearing female subjects (SAD/MAD) and male and non-childbearing female patients with mild asthma;
• Healthy subjects as determined by past medical history, vitals, physical examination and 12-lead ECG, clinical laboratory tests.
• Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive, weight ≥50 kg;
• Non-smokers or ex-smokers
• Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the subject; able to comply with protocol requirements and or study procedure;
• Negative screen for drugs of abuse and alcohol at screening and on admission.
• Male subjects should agree not to donate sperm for 3 months post dose; and
• Female partners (of child bearing potential) of male subjects should use 2 methods of highly effective contraception for 3 months post last

Additionally for POC

• Pre- bronchodilator Forced expiratory volume in 1 sec( FEV1) of > 70% (adjusted for age, sex and race)
• Steroid naïve subjects with history of mild asthma that satisfy the Global Initiative for Asthma (GINA) definition of asthma, but otherwise healthy.

Exclusion criteria

• Subjects with evidence or history of clinically significant medical history.
• History of tuberculosis (TB) and/or a positive Tuberculin Skin Test and/or QuantiFeron- TB®-Gold test.
• Use of any immunotherapy within 3 months prior to screening.
• History of serious adverse reaction, severe hypersensitivity or allergy to any drug/drug substance (except house dust mite, pollen allergens or cat dander allergy in asthmatics) or in any other circumstance (e.g. anaphylaxis);
• Abnormal liver function
• Positive screen on hepatitis-B surface antigen (HBsAg), antibodies to the hepatitis C (HCV) or antibodies to the human immunodeficiency virus (HIV) 1,2;

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

57 participants in 2 patient groups, including a placebo group

RP3128

Experimental group

Description:

RP3128, A CRAC channel modulator

Treatment:

Drug: RP3128

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo